Gleiss Lutz is advising oncology-focused biotech company Agennix Incorporated, based in Houston (Texas), on the merger with GPC Biotech AG. As part of the deal GPC Biotech will be merged into a new German company which will hold the shares of Agennix and receive a EUR 15 million cash contribution from dievini Hopp BioTech holding GmbH & Co. KG, one of GPC’s main shareholders.
The new publicly listed German stock corporation (AG) will have sites in Munich, Princeton and Houston and will focus on the development of new cancer treatment therapies. The consolidated know-how of the two biotech specialists as well the human and financial resources are to be used for the development of Agennix’s talactoferrin, a novel oral agent for lung, kidney and other cancers.
Gleiss Lutz is jointly advising Agennix on this transaction together with leading US law firm Fulbright & Jaworski.
Gleiss Lutz’ team consists of the following lawyers: Dr. Ralf Morshäuser and Peter Steffen Carl (both partners, lead, corporate, Munich), Dr. Stephan Aubel (partner, capital markets, Frankfurt), Dr. Tobias Falkner, Stephan Meyer (both corporate, Munich), Dr. Michael Marquardt (partner), Dr. Stefan Mayer (both tax, Frankfurt) and Dr. Jan Balssen (antitrust, Munich).
Fulbright & Jaworski (advising on the US legal aspects of the deal): Robert E. Wilson (partner, lead corporate, Houston/Munich), Andrius R. Kontrimas, Stephanie Schroepfer (both partners, tax, Houston), Martin D. Doublesin, Valorie Wanner, Joel Smith (all corporate, Houston), Ron Scharnberg (tax, Houston).
Forward
